Navigation Links
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Date:8/19/2007

trial, could potentially support an accelerated registration strategy for tanespimycin in this life-threatening disease."

The TIME clinical program will utilize Kosan's improved, proprietary injectable suspension formulation of tanespimycin injectable suspension. The formulation is designed to provide important benefits, including improved patient safety, due to the elimination of Cremophor(R) and the associated need for steroid premedication to prevent hypersensitivity reactions. Tanespimycin injectable suspension also has a potentially enhanced intellectual property position and permits easier drug preparation and administration compared to the prior formulation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is anticipated to enroll approximately 130 patients. Key aspects of the TIME-2 trial are as follows.

-- The trial is designed to test three different doses of tanespimycin in

combination with the approved dose and schedule of bortezomib

(1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and

340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour

intravenous infusion on a cycle of two weeks of treatment every three

weeks (the same schedule as bortezomib).

-- Patients eligible to participate in the TIME-2 trial must have been

treated with and progressed following at least three prior treatments

for multiple myeloma. Prior regimens must include bortezomib and

lenalidomide (Revlimid(R)).

-- The primary endpoint of the trial is the dose response based on

objective response rate after 4 cycles of treatment. Secondary

endpoints include a comparison of response rate between the dose

groups, progression-free survival, time to treatment failure and

overall survival. Objective response rate in multiple myeloma is

measured primarily by the pa
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- Market ... Hydrochloride Industry, 2009-2019 is a professional and ... Oxybutynin Hydrochloride industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Oxybutynin Hydrochloride listing their product ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
(Date:9/19/2014)... September 19, 2014 According ... Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise ... Advanced technologies - Global Forecast to 2019" published ... to reach $19,786.3 Million by 2019 from $14,240.0 ... from 2014 to 2019. Browse 74 ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
(Date:9/20/2014)... (PRWEB) September 20, 2014 The first ... is now in its third week in the U.S. ... LLC reports. Court documents indicate that the week opened ... with testimony from a DePuy Orthopaedics vice president, who ... of the company’s Pinnacle hip replacement. According to Reuters, ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
(Date:9/19/2014)... 20, 2014 Nearly 780 Risperdal lawsuits ... Pleas where a meeting took place to discuss the ... in the court’s mass tort program. Attorneys for ... past week at the Complex Litigation Center in Philadelphia’s ... pretrial proceedings. The Risperdal lawsuits filed against Johnson & ...
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
Breaking Medicine News(10 mins):Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... (BRONX, NY) The National Institute of Diabetes and ... of Health (NIH) has awarded Albert Einstein College of ... for the continuation of its Diabetes Research and Training ... supplemental grant for equipment and additional pilot and feasibility ...
... and a friend dares you to eat a raw crayfish ... a severe parasitic infection. Physicians at Washington University School of ... six people who had consumed raw crayfish from streams and rivers ... three have been diagnosed since last September; the latest in April. ...
... high-risk women opt for lumpectomy , TUESDAY, May 25 ... before surgery enhances their chances of being able to ... new research suggests. , The observation was based on ... United States. It focused on postmenopausal women who had ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
... indicated higher, lower risk of disease, study finds , ... germs living in your gut could affect your risk ... signs of the existence of some germs "are more ... can develop into cancer, while other bacterial signatures are ...
... in French . Montreal, May 25, 2010 ... French and English, at local bookstores and pharmacies. Dr. Jean-Daniel ... Department of Ophthalmology, along with two colleagues from France, have ... Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate ...
Cached Medicine News:Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:Breast Cancer Study Offers New Hope 2Health News:Book on vision loss: AMD affects 1 million Canadians 2
... catheter is designed to remove thrombus ... saline jets travel backwards at half ... a low pressure zone causing a ... the catheter where it is fragmented ...
... Electroanatomical Mapping System combines the legendary accuracy ... ease of Windows* software. It integrates ... new tools that enhance your clinical capabilities ... into the future of EP. The ...
... are meeting the clinical needs of ... anesthesiologists. And, they are of the ... Medtronic.,Effective pacing with the adjustment of ... quick battery changes. Both the ...
... The Kantrowitz CardioVad is a unique left ventricular ... more effectively. It is being used in a ... heart failure as part of an FDA-approved Feasibility ... and disconnect the external power source for minutes ...
Medicine Products: